Adaptimmune Therapeutics

$1.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.69%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!

About ADAP

Adaptimmune Therapeutics plc American Depositary Shares, also called Adaptimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Employees
430
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
151.36M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
330.26K
High Today
$1.55
Low Today
$1.40
Open Price
$1.44
Volume
290.89K
52 Week High
$14.54
52 Week Low
$1.40

Collections

ADAP News

ReutersAug 4

Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT

96

ADAP Earnings

-$0.33
-$0.22
-$0.10
$0.01
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, Pre-Market

Popular Stocks

More ADAP News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.